Royalty Pharma plc (RPRX)

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021.

Robust quarterly performance with royalty receipts and adjusted EBITDA by +11% and +13%, respectively. New catalysts are emerging with recurrent billion‑dollar transactions and Chinese royalty opportunities. Shareholder returns remain strong and are combined with a valuation discount. We remain buyers.

Royalty Pharma (RPRX) Q2 Receipts Up 20%

Royalty Pharma plc (NASDAQ:RPRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Marshall Jonathan Urist - Executive Vice President of Research & Investments Pablo Gerardo Legorreta - Founder, Chairman of the Board & CEO Terrance P. Coyne - Executive VP & CFO Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Christopher Thomas Schott - JPMorgan Chase & Co, Research Division Geoffrey Christopher Meacham - Citigroup Inc., Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Royalty Pharma (RPRX) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $0.96 per share a year ago.

Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $364 million Raised full year 2025 guidance: Portfolio Receipts expected to be $3,050 to $3,150 million NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) --  Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “We delivered excellent second quarter 2025 results, as the strength of our diversified portfolio drove 20% growth in Portfolio Receipts, and raised our full year guidance,” said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer.

Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.

CNBC's Joe Kernen reports on the latest news.

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global private equity firm focused on growth investing.

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. The Revolution Medicines royalty deal provides near-term upside and de-risks pipeline assets, with pivotal data expected in 2026. We forecast 2025 EPS of $4.53 and raise our target price to $45.3, reflecting strong earnings and capital deployment.

Royalty Pharma said on Tuesday will pay up to $2 billion to Revolution Medicines to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib.